The pharmacogenomics of membrane transporters project: Research at the interface of genomics and transporter pharmacology

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 1, 2010, Pages 109-116

  Kroetz, D L ^a   Yee, S W ^a   Giacomini, K M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE FREQUENCY; GENETIC VARIABILITY; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; MEDICAL RESEARCH; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SEQUENCE; ANIMALS; GENE FREQUENCY; GENOME, HUMAN; GENOMICS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR SEQUENCE DATA; PHARMACOGENETICS;

EID: 72849150876     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.226     Document Type: Article

References (34)

1. Chen, Y. et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 9, 127-136 (2009).
2. Leabman, M.K. et al. Pharmacogenetics of Membrane Transporters Investigators. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl. Acad. Sci. U.S.A. 100, 5896-5901 (2003).
3. abla, N. et al. The human multidrug resistance protein 4 (MRP4, aBCC4): functional analysis of a highly polymorphic gene. J. Pharmacol. Exp. Ther. 325, 859-868 (2008).
4. Urban, T.J. et al. Functional genetic diversity in the high-afnity carnitine transporter OCTN2 (SLC22a5). Mol. Pharmacol. 70, 1602-1611 (2006).
5. Shu, Y. et al. Pharmacogenetics of Membrane Transporters Investigators. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. U.S.A. 100, 5902-5907 (2003).
6. Erdman, A.R. et al. The human organic anion transporter 3 (OaT3; SLC22a8): genetic variation and functional genomics. Am. J. Physiol. Renal Physiol. 290, F905-F912 (2006).
7. Urban, T.J. et al. Functional genomics of membrane transporters in human populations. Genome Res. 16, 223-230 (2006).
8. Shu, Y. et al. Efect of genetic variation in the organic cation transporter 1, OCT1 on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83, 273-280 (2008).
9. Urban, T.J., Giacomini, K.M. & Risch, N. Haplotype structure and ethnic-specifc allele frequencies at the OCTN locus: implications for the genetics of Crohn's disease. Infamm. Bowel Dis. 11, 78-79 (2005).
10. Gray, J.H. et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol. Pharmacol. 65, 512-519 (2004).
11. Leabman, M.K. et al. Pharmacogenetics of Membrane Transporters Investigators. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12, 395-405 (2002).
12. Hesselson, S.E. et al. Genetic variation in the proximal promoter of aBC and SLC superfamilies: liver and kidney specifc expression and promoter activity predict variation. PLoS ONE 4, e6942 (2009).
13. Yee, S.W. et al. Identifcation and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28a2). J. Pharmacol. Exp. Ther. 328, 699-707 (2009).
14. Choi, J.H. et al. Identifcation and characterization of novel polymorphisms in the basal promoter of the human transporter, MaTE1. Pharmacogenet Genomics 2009; e-pub ahead of print 9 September 2009.
15. Tahara, H. et al. Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22a4) and OCTN2 (SLC22a5). J. Pharmacol. Exp. Ther. 329, 262-271 (2009).
16. Kelly, L., Karchin, R. & Sali, A. Protein interactions and disease phenotypes in the aBC transporter superfamily. Pac. Symp. Biocomput. 51-63 (2007).
17. Li, M. et al. Selecting optimum eukaryotic integral membrane proteins for structure determination by rapid expression and solubilization screening. J. Mol. Biol. 385, 820-830 (2009).
18. Shu, Y. et al. Efect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007).
19. Chen, Y. et al. Efect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 19, 497-504 (2009).
20. Urban, T.J. et al. Efects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin. Pharmacol. Ther. 83, 416-421 (2008).
21. Urban, T.J. et al. Functional efects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22a4). Pharmacogenet. Genomics 17, 773-782 (2007).
22. Fujita, T. et al. Functional analysis of polymorphisms in the organic anion transporter, SLC22a6 (OaT1). Pharmacogenet. Genomics 15, 201-209 (2005).
23. Owen, R.P. et al. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet. Genomics 15, 83-90 (2005).
24. Badagnani, I. et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28a3). Pharmacogenomics J. 5, 157-165 (2005).
25. Owen, R.P. et al. Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab. Dispos. 34, 12-15 (2006).
26. Badagnani, I. et al. Interaction of methotrexate with organic-anion transporting polypeptide 1a2 and its genetic variants. J. Pharmacol. Exp. Ther. 318, 521-529 (2006).
27. Anderle, P. , Nielsen, C.U., Pinsonneault, J., Krog, P.L., Brodin, B. & Sadée, W. Genetic variants of the human dipeptide transporter PEPT1. J. Pharmacol. Exp. Ther. 316, 636-646 (2006).
28. Pinsonneault, J., Nielsen, C.U. & Sadée, W. Genetic variants of the human H+/ dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. Exp. Ther. 311, 1088-1096 (2004).
29. Jeong, H., Herskowitz, I., Kroetz, D.L. & Rine, J. Function-altering SNPs in the human multidrug transporter gene aBCB1 identifed using a Saccharomyces-based assay. PLoS Genet. 3, e39 (2007).
30. Gow, J.M., Hodges, L.M., Chinn, L.W. & Kroetz, D.L. Substrate-dependent efects of human aBCB1 coding polymorphisms. J. Pharmacol. Exp. Ther. 325, 435-442 (2008).
31. Burman, J., Tran, C.H., Glatt, C., Freimer, N.B. & Edwards, R.H. The efect of rare human sequence variants on the function of vesicular monoamine transporter 2. Pharmacogenetics 14, 587-594 (2004).
32. Glatt, C.E. et al. Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat. Genet. 27, 435-438 (2001).
33. Innocenti, F. et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27, 2604-2614 (2009).
34. De Jong, F.A. et al. Irinotecan-induced diarrhea: functional signifcance of the polymorphic aBCC2 transporter protein. Clin. Pharmacol. Ther. 81, 42-49 (2007).